For oral drug delivery, these initial results indicate the potential of minimizing the exposure of harmful drug to the stomach and delivering chemotherapeutic payloads to the small intestines capable of traveling to and reducing colonic tumors. Future work includes developing a doxorubicin-inulin conjugate which will utilize colonic microbiota to digest the conjugate and thus release free doxorubicin directly in the colon.
展开▼